Biolojic Design vs LabGenius (2026)
Both design multispecific antibodies with machine learning and run a mix of partnered and in house programs, and they emphasize different things. Biolojic Design engineers antibodies with designed functions, agonists, antagonists, conditional binders and its multibodies that bind more than one target on a single arm, and its approach has reached a human trial through AU-007 with Aulos Bioscience. Its programs include TEV-325 with Teva and a collaboration with Merck KGaA. LabGenius pairs its EVA machine learning engine with laboratory robotics, focused on T cell engagers for solid tumors where the problem is hitting the tumor without harming healthy tissue, and its lead is LGTX-101, a Nectin-4 by CD3 engager, with an LG Chem collaboration. Biolojic is the one for antibodies with a designed mechanism and a route to the clinic already shown. LabGenius is the one for tumor selective T cell engagers built through an automated design and test loop.
- Antibodies engineered as functional switches, including multispecific multibodies on a single arm.
- A platform whose design reached a human trial through a partner, AU-007 with Aulos Bioscience.
- Named programs in autoimmune disease and cancer, with Teva and Merck KGaA.
- An automated machine learning and robotics engine, EVA, focused on tumor selective antibodies.
- A lead T cell engager, LGTX-101, targeting Nectin-4 and CD3 for solid tumors.
- A collaboration with LG Chem against a solid tumor antigen, with its own pipeline alongside.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Biolojic Design and LabGenius are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Biolojic Design | LabGenius |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | Not recorded | 2012 |
| Headquarters | Rehovot, Israel | London, United Kingdom |
| Website | biolojic.com | labgeni.us |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Biolojic Design uses machine learning to design antibodies that do more than block a target: epitope specific agonists and antagonists, conditional binders, and what it calls multibodies, single symmetrical antibodies that bind more than one target on the same arm. It is based in Israel and develops programs both on its own and with partners.
Source: AI Health Index, October 2026
LabGenius designs antibody drugs for cancer using a machine learning engine wired into its own robotic lab, and develops them through a mix of partnerships and a wholly owned pipeline. It is based in London and was founded in 2012 by chief executive James Field.
Source: AI Health Index, October 2026
Questions buyers ask
How are Biolojic Design and LabGenius priced and sold?
Biolojic earns through its own pipeline and its partnerships rather than selling access to the design engine, so no price appears.
LabGenius earns through partnerships rather than selling access to EVA, so there is no price to quote. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 9, 2026. No vendor pays for placement.
How do Biolojic Design and LabGenius handle patient data?
Biolojic publishes no answer, so that handling is undescribed.
For LabGenius, no protected health information is involved, since the inputs are protein designs and assay data. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 9, 2026. No vendor pays for placement.
Which settings and specialties do Biolojic Design and LabGenius cover?
Biolojic works in autoimmune disease, where TEV-325 targets atopic dermatitis and asthma, and in cancer, where BD200 is a multibody drug conjugate and AU-007 reached a trial in cancer patients.
LabGenius concentrates on multispecific antibodies for solid tumors, where the problem it names is hitting the tumor without harming healthy tissue, and the lead program LGTX-101 puts a specific target pair behind that, Nectin-4 and CD3. The LG Chem collaboration adds a further solid tumor antigen, though unnamed. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 9, 2026. No vendor pays for placement.
What evidence is published for Biolojic Design and LabGenius?
For Biolojic Design, the company's own lead, TEV-325, a multibody partnered with Teva, entered investigational new drug enabling studies for atopic dermatitis and asthma in 2025, and a multi target discovery collaboration ran with Merck KGaA.
LabGenius describes reaching a candidate after roughly four design and test cycles of about six weeks each, which is a concrete claim about how the loop runs. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 9, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed in October 2026. Neither publishes a price, and both run a mix of partnered and wholly owned programs.
Ask both which programs have advanced and through whom, and how each reports the designs that did not work.